&lt;p&gt;miR-596 suppresses the expression of Survivin and enhances the sensitivity of osteosarcoma cells to the molecular targeting agent anlotinib&lt;/p&gt;

Wang, Leisheng; en, H. S. C.; Yang, Lei; Zhang, Yanbing; Sun, Baisheng; Gao, Jinliang

doi:10.2147/ott.s215145

Cited by 14 publications

(8 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ma et al (31) reported that miR-6077 inhibited the expression of glucose transporter 1 and enhanced the anti-tumor effect of anlotinib on patient-derived lung adenocarcinoma cells. Another study indicated that miR-596 promoted the sensitivity of osteosarcoma to anlotinib by targeting survivin (32). Furthermore, Lu et al (33) revealed that supplementing exogenous C-X-C chemokine ligand 2 (CXCL2) may be a possible mechanism by which to circumvent anlotinib resistance.…”

Section: Preclinical Studies On Anlotinibmentioning

confidence: 99%

Anlotinib as a molecular targeted therapy for tumors (Review)

2020

View full text Add to dashboard Cite

Angiogenesis has an essential role in tumor growth and metastasis, and blocking this pathway has been a successfully utilized strategy in the clinical treatment of cancer. Anlotinib (AL3818) is a novel oral receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 and 3, fibroblast growth factor 1-4, platelet-derived growth factor receptor α and β, c-Kit and Ret. Anlotinib exerts inhibitory effects on tumor growth and angiogenesis and received its first approval as a third-line treatment for refractory advanced non-small-cell lung cancer in May 2018 and its second approval as a second-line treatment for advanced soft-tissue sarcoma in June 2019 in the People's Republic of China. Anlotinib has encouraging efficacy and a manageable and tolerable safety profile in a broad range of malignancies, including medullary thyroid cancer, renal cell cancer, gastric cancer and esophageal squamous cell carcinoma. In the present review, the preclinical and clinical trials of anlotinib were summarized with a focus on safety evaluation and adverse event management.

show abstract

Section: Preclinical Studies On Anlotinibmentioning

confidence: 99%

Anlotinib as a molecular targeted therapy for tumors (Review)

2020

View full text Add to dashboard Cite

show abstract

“…In melanoma cells, elevated expression of miR-596 leads to enhanced cell apoptosis by targeting two apoptotic proteins [31]. Overexpression of miR-596 in osteosarcoma cells can promote the toxicity effect of anlotinib via the regulation of survivin [32]. Based on the tumor-suppressive role of miR-596 in gastric cancer [20], we first establish that circPRRX1 directly modulates miR-596 through a binding site.…”

Section: Discussionmentioning

confidence: 99%

Exosomal circPRRX1 functions as a ceRNA for miR-596 to promote the proliferation, migration, invasion, and reduce radiation sensitivity of gastric cancer cells via the upregulation of NF-κB activating protein

Zheng

Yuan

et al. 2022

Anti-Cancer Drugs

View full text Add to dashboard Cite

Exosomes, which are small extracellular vesicles, have been unveiled to carry circular RNAs (circRNAs). CircRNA paired-related homeobox 1 (circPRRX1) can be transferred by exosomes derived from gastric cancer cells. Here, we investigated the activity and mechanism of exosomal circPRRX1 in gastric tumorigenesis and radiation sensitivity. CircPRRX1, microRNA (miR)-596, and NF-κB activating protein (NKAP) were quantified by quantitative real-time PCR and immunoblotting. Cell proliferation, motility, and invasion were detected by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide and transwell assays, respectively. Cell colony formation and survival were assessed by colony formation assays. Dual-luciferase reporter assays were performed to verify the direct relationship between miR-596 and circPRRX1 or NKAP. In-vivo xenograft studies were used to evaluate the role of exosomal circPRRX1 in tumor growth. Our data showed that circPRRX1 expression was elevated in human gastric cancer, and circPRRX1 could be transferred by exosomes from gastric cancer cells. Exosomal circPRRX1 affected cell proliferation, motility, invasion, and radiation sensitivity in vitro and tumor growth in vivo. Mechanistically, circPRRX1 directly regulated miR-596 expression, and exosomal circPRRX1 affected cell biological functions at least in part through miR-596. NKAP was identified as a direct target and functionally downstream effector of miR-596. Exosomal circPRRX1 modulated NKAP expression by acting as a competing endogenous RNA (ceRNA) for miR-596. Our findings suggest a new mechanism, the exosomal circPRRX1/ miR-596/NKAP ceRNA crosstalk, in regulating gastric tumorigenesis and radiation sensitivity. Anti-Cancer Drugs 33: 1114

show abstract

“…The abnormal expression of miRNA is also closely related to the disease [ 36 , 37 ]. Of the three predicted miRNAs, MiR-658 is overexpressed in gastric cancer and induces gastric cancer metastasis by activating the PAX3-MET pathway [ 38 ], while miR-504 can inhibit cell proliferation and migration in non-small-cell lung cancer [ 39 ], oral squamous cell carcinoma [ 40 ], liver cancer [ 41 ], and overexpression in osteosarcoma [ 42 ], and breast cancer [ 43 ] to enhance the growth and metastasis of tumors.…”

Section: Discussionmentioning

confidence: 99%

lncRNA MSTRG.29039.1 Promotes Proliferation by Sponging hsa‐miR‐12119 via JAK2/STAT3 Pathway in Multiple Myeloma

Liu

Han

Meng

et al. 2021

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Noncoding RNA (ncRNA) is involved in the occurrence, development, metastasis, and drug resistance of tumors and involves a variety of biological functions. In addition, miRNA can regulate proliferation and migration and even regulate epigenetics to promote the development of multiple myeloma (MM). However, the mechanism of ncRNA involved in MM is still unclear, and there are many unknown ncRNAs to be explored. This research is aimed at discovering the unknown lncRNA in MM through high-throughput sequencing and to study the mechanism and role of competitive endogenous RNA (ceRNA) involved in the pathogenesis of MM for the development of novel molecular markers and potential new targeted drugs. We screened out 262 new lncRNAs with statistical differences by RNA sequencing and selected the lncRNA MSTRG.29039.1 according to the expression and function of lncRNAs and their target genes in MM. We verified that MSTRG.29039.1 and its target gene OSMR were highly expressed in MM. After knockdown of MSTRG.29039.1 in MM cell lines, the expression of OSMR was decreased, and the expression of hsa-miR-12119 was upregulated which can also promote cell apoptosis and inhibit proliferation. Then, we knocked down hsa-miR-12119 and MSTRG.29039.1, we found that apoptosis of MM cells was reduced, and cell proliferation was increased compared with just knocking down hsa-miR-12119. We further verified the direct binding relationship between MSTRG.29039.1 and OSMR by the dual-luciferase reporter assay system. Thus, MSTRG.29039.1 can competitively bind with miRNA to counteract the inhibitory effect of miRNA on OSMR, which regulates cell proliferation and apoptosis through the JAK2/STAT3 pathway. In a conclusion, lncRNA MSTRG.29039.1 could promote proliferation by sponging hsa-miR-12119 via the JAK2/STAT3 pathway in multiple myeloma. This may be a molecular marker and a potential therapeutic target for MM.

show abstract

<p>miR-596 suppresses the expression of Survivin and enhances the sensitivity of osteosarcoma cells to the molecular targeting agent anlotinib</p>

Cited by 14 publications

References 68 publications

Anlotinib as a molecular targeted therapy for tumors (Review)

Anlotinib as a molecular targeted therapy for tumors (Review)

Exosomal circPRRX1 functions as a ceRNA for miR-596 to promote the proliferation, migration, invasion, and reduce radiation sensitivity of gastric cancer cells via the upregulation of NF-κB activating protein

lncRNA MSTRG.29039.1 Promotes Proliferation by Sponging hsa‐miR‐12119 via JAK2/STAT3 Pathway in Multiple Myeloma

Contact Info

Product

Resources

About